4.6 Article

Use of quantitative T2 mapping for the assessment of renal cell carcinomas: first results

Journal

CANCER IMAGING
Volume 19, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s40644-019-0222-8

Keywords

MRI mapping techniques; Quantitative MRI; T2 mapping; Clear cell renal cell carcinoma; Tumor grading

Funding

  1. Abbott
  2. Actelion Pharmaceuticals
  3. Bayer Schering Pharma
  4. Bayer Vital
  5. BRACCO Group
  6. Bristol-Myers Squibb
  7. Charite research organisation GmbH
  8. Deutsche Krebshilfe
  9. Dt. Stiftung fur Herzforschung
  10. Essex Pharma
  11. Fibrex Medical Inc.
  12. Focused Ultrasound Surgery Foundation
  13. Fraunhofer Gesellschaft
  14. Guerbet
  15. InSightec Ud.
  16. IPSEN Pharma
  17. Kendlel MorphoSys AG
  18. Lilly GmbH
  19. Lundbeck GmbH
  20. MeVis Medical Solutions AG
  21. Nexus Oncology
  22. Novartis
  23. Parexel Clinical Research Organisation Service
  24. Perceptive
  25. Pfizer GmbH
  26. Philipps
  27. SanofisAventis S. A
  28. Siemens
  29. Spectranetics GmbH
  30. Terumo Medical Corporation
  31. TNS Healthcare GMbH
  32. Toshiba
  33. UCB Pharma
  34. Wyeth Pharma
  35. Zukunftsfond Berlin (TSB)
  36. Amgen
  37. AO Foundation
  38. BARD
  39. BBraun
  40. Boehring Ingelheimer
  41. Brainsgate
  42. PPD (Clinical Research Organisation)
  43. CELLACT Pharma
  44. Celgene
  45. CeloNova BioSciences
  46. Covance
  47. Deviees, Ine. USA
  48. Ganymed
  49. Gilead Sciences
  50. Glaxo Smith Kline
  51. ICON (Clinical Research Organisation)
  52. Jansen
  53. LUX Bioseienees
  54. MedPass
  55. Merek
  56. Mologen
  57. Nuvisan
  58. Pluristem
  59. Quintiles
  60. Roehe
  61. Sehumaeher GmbH
  62. Seattle Geneties
  63. Symphogen
  64. TauRx Therapeuties Ud.
  65. Accovion
  66. AIO: Arbeitsgemeinschaft Internistische Onkologie
  67. ASR Advanced sleep research
  68. Astellas
  69. Theradex
  70. Galena Biopharma
  71. Chiltern
  72. PRAint
  73. Inspiremd
  74. Medronic
  75. Respicardia
  76. Silena Therapeutics
  77. Spectrum Pharmaceuticals
  78. St. Jude.
  79. TEVA
  80. Theorem
  81. Abbvie
  82. Aesculap
  83. Biotronik
  84. Inventivhealth
  85. ISA Therapeutics
  86. LYSARC
  87. MSD
  88. novocure
  89. Ockham oncology
  90. Premier-research
  91. Psi-cro
  92. Tetec-ag
  93. Winickernorimed
  94. Achaogen Inc.
  95. ADIR
  96. AstraZenaca AB
  97. Demira Inc.
  98. Euroscreen S. A.
  99. Galmed Research and Development Ltd.
  100. GETNE
  101. Guidant Europe NV
  102. Holaira Inc.
  103. Immunomedics Inc.
  104. Innate Pharma
  105. Isis Pharmaceuticals Inc.
  106. Kantar Health GmbH
  107. MedImmune Inc.
  108. Medpace Germany GmbH (CRO)
  109. Merrimack Pharmaceuticals Inc.
  110. Millenium Pharmaceuticals Inc.
  111. Orion Corporation Orion Pharma
  112. Pharmacyclics Inc.
  113. PIQUR Therapeutics Ltd.
  114. Pulmonx International Sarl
  115. Servier (CRO)
  116. SGS Life Science Services (CRO)
  117. Treshold Pharmaceuticals Inc.
  118. Deutsche Forschungsgemeinschaft (DFG) [SFB 1340/1 2018, 5943/31/41/91]
  119. Charite - Universitaetsmedizin Berlin
  120. Berlin Institute of Health
  121. EU Programmes
  122. INC Research

Ask authors/readers for more resources

BackgroundCorrect staging and grading of patients with clear cell renal cell carcinoma (cRCC) is of clinical relevance for the prediction of operability and for individualized patient management. As partial or radial resection with postoperative tumor grading currently remain the methods of choice for the classification of cRCC, non-invasive preoperative alternatives to differentiate lower grade from higher grade cRCC would be beneficial.MethodsThis institutional-review-board approved cross-sectional study included twenty-seven patients (8 women, mean ageSD, 61.314.2) with histopathologically confirmed cRCC, graded according to the International Society of Urological Pathology (ISUP). A native, balanced steady-state free precession T2 mapping sequence (TrueFISP) was performed at 1.5T. Quantitative T2 values were measured with circular 2D ROIs in the solid tumor portion and also in the normal renal parenchyma (cortex and medulla). To estimate the optimal cut-off T2 value for identifying lower grade cRCC, a Receiver Operating Characteristic Curve (ROC) analysis was performed and sensitivity and specificity were calculated. Students' t-tests were used to evaluate the differences in mean values for continuous variables, while intergroup differences were tested for significance with two-tailed Mann-Whitney-U tests.ResultsThere were significant differences between the T2 values for lower grade (ISUP 1-2) and higher grade (ISUP 3-4) cRCC (p<0.001), with higher T2 values for lower grade cRCC compared to higher grade cRCC. The sensitivity and specificity for the differentiation of lower grade from higher grade tumors were 83.3% (95% CI: 0.59-0.96) and 88.9% (95% CI: 0.52-1.00), respectively, using a threshold value of 110ms. Intraobserver/interobserver agreement for T2 measurements was excellent/substantial.ConclusionsNative T2 mapping based on a balanced steady-state free precession MR sequence might support an image-based distinction between lower and higher grade cRCC in a two-tier-system and could be a helpful addition to multiparametric imaging.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available